Home / Market News / $INSP
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Baird Maintains Neutral Rating on Inspire Medical Systems and Raises Price Target

Nov 3, 2026, 10:34 PM UTC · Primary ticker $INSP

Baird has reiterated its 'Neutral' rating on Inspire Medical Systems while modestly increasing its price target from $73 to $77. This indicates a slightly more optimistic outlook on the stock's valuation without a change in the fundamental investment recommendation.

Baird maintained its 'Neutral' rating on Inspire Medical Systems, suggesting they see the stock as fairly valued at its current levels, despite a slight increase in their price target from $73 to $77. This 5.5% price target bump indicates a minor upward revision in their valuation model, potentially due to updated financial projections or market comparables. For traders, this is a moderately positive signal, as it suggests continued analyst coverage and a slightly higher perceived intrinsic value, but it doesn't fundamentally change the investment thesis. Short-term, the stock might see a small positive reaction, but long-term implications are limited without a rating upgrade. The key risk for traders is that a 'Neutral' rating often implies limited upside potential from current prices.

$INSP neutral Analyst rating maintained, price target raised
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.